---
title: "Zhejiang Anglikang Pharmaceutical Co.,Ltd. (002940.SZ)"
type: "Symbol"
locale: "en"
url: "https://longbridge.com/en/quote/002940.SZ.md"
symbol: "002940.SZ"
name: "Zhejiang Anglikang Pharmaceutical Co.,Ltd."
industry: "Pharmaceuticals"
datetime: "2026-05-20T03:36:28.999Z"
locales:
  - [en](https://longbridge.com/en/quote/002940.SZ.md)
  - [zh-CN](https://longbridge.com/zh-CN/quote/002940.SZ.md)
  - [zh-HK](https://longbridge.com/zh-HK/quote/002940.SZ.md)
---

# Zhejiang Anglikang Pharmaceutical Co.,Ltd. (002940.SZ)

## Company Overview

Zhejiang AngLiKang Pharmaceutical CO.,LTD., a pharmaceutical company, engages in manufacturing APIs and pharmaceutical preparations for oral cephalosporins, cardiovascular, and kidney diseases. The company also offers products in the areas of anti-infection, cardiovascular, urinary system (nephropathy), anesthesia and pain, and anti-androgen. The company was founded in 2001 and is based in Shengzhou, China.

| Item | Detail |
|------|--------|
| Industry | Pharmaceuticals |
| Exchange | CN Market |
| Website | [www.alkpharm.com](https://www.alkpharm.com) |

## Key Drivers
> *AI-analyzed key factors driving this stock's performance*


## Longbridge Financial Score™: C
> *Longbridge Financial Score™ — Proprietary multi-factor rating model by Longbridge*
> Updated: 2026-05-19T04:30:08.000Z

**Overall: C (0.45)**

**Industry**: Pharmaceuticals

| Metric | Value |
|--------|-------|
| Industry Ranking | 107 / 215 |
| Industry Median | C |
| Industry Average | C |

- **Style**: Blend - Stocks in which the company has both growth and mature businesses.
- **Scale**: Small - The company's operation has a high degree of growth and volatility, making it easy to achieve high investment returns.

**Multi Score**: C

#### Style Score Score: 

| Indicator | Value | Rating |
|-----------|-------|--------|
| Revenue YoY | -2.15% |  |
| Net Profit YoY | 86.98% |  |
| P/B Ratio | 5.14 |  |
| Dividend Ratio | 0.52% |  |

#### Size Score Score: 

| Indicator | Value | Rating |
|-----------|-------|--------|
| Market Cap | 8454416450.56 |  |
| Revenue | 1418080001.08 |  |

#### Multi Score Score: C

| Indicator | Value | Rating |
|-----------|-------|--------|
| ROE | 7.96% | B |
| Profit Margin | 8.96% | B |
| Gross Margin | 36.62% | B |
| Revenue YoY | -2.15% | D |
| Net Profit YoY | 86.98% | A |
| Total Assets YoY | 6.75% | B |
| Net Assets YoY | 4.76% | C |
| Cash Flow Margin | 156.94% | B |
| OCF YoY | -2.15% | D |
| Turnover | 0.47 | C |
| Gearing Ratio | 39.27% | B |

```chart-data:radar
{
  "title": "Longbridge Financial Score - Zhejiang Anglikang Pharmaceutical Co.,Ltd.",
  "chart_type": "radar",
  "dimensions": [
    {
      "name": "Style Score",
      "grade": "",
      "indicators": [
        {
          "name": "Revenue YoY",
          "value": "-2.15%",
          "rating": ""
        },
        {
          "name": "Net Profit YoY",
          "value": "86.98%",
          "rating": ""
        },
        {
          "name": "P/B Ratio",
          "value": "5.14",
          "rating": ""
        },
        {
          "name": "Dividend Ratio",
          "value": "0.52%",
          "rating": ""
        }
      ]
    },
    {
      "name": "Size Score",
      "grade": "",
      "indicators": [
        {
          "name": "Market Cap",
          "value": "8454416450.56",
          "rating": ""
        },
        {
          "name": "Revenue",
          "value": "1418080001.08",
          "rating": ""
        }
      ]
    },
    {
      "name": "Multi Score",
      "grade": "C",
      "indicators": [
        {
          "name": "ROE",
          "value": "7.96%",
          "rating": "B"
        },
        {
          "name": "Profit Margin",
          "value": "8.96%",
          "rating": "B"
        },
        {
          "name": "Gross Margin",
          "value": "36.62%",
          "rating": "B"
        },
        {
          "name": "Revenue YoY",
          "value": "-2.15%",
          "rating": "D"
        },
        {
          "name": "Net Profit YoY",
          "value": "86.98%",
          "rating": "A"
        },
        {
          "name": "Total Assets YoY",
          "value": "6.75%",
          "rating": "B"
        },
        {
          "name": "Net Assets YoY",
          "value": "4.76%",
          "rating": "C"
        },
        {
          "name": "Cash Flow Margin",
          "value": "156.94%",
          "rating": "B"
        },
        {
          "name": "OCF YoY",
          "value": "-2.15%",
          "rating": "D"
        },
        {
          "name": "Turnover",
          "value": "0.47",
          "rating": "C"
        },
        {
          "name": "Gearing Ratio",
          "value": "39.27%",
          "rating": "B"
        }
      ]
    }
  ]
}
```

## Valuation Analysis

| Metric | Current | Industry Ranking | High | Median | Low |
|--------|---------|-----------------|------|--------|-----|
| PE (TTM) | 69.06 | 120/215 | 111.50 | 70.55 | 59.39 |
| PB | 5.34 | 192/215 | 5.40 | 4.64 | 4.03 |
| PS (TTM) | 6.19 | 145/215 | 5.95 | 5.06 | 4.38 |
| Dividend Yield | 0.50% | 133/215 | 0.68% | 0.59% | 0.29% |

## Peer Comparison

| Rank | Name | Profit | Growth | Operation | Security | Cash | Rating |
| --- | --- | --- | --- | --- | --- | --- | --- |
| 01 | Allist (688578.SH) | A | A | B | A | B | A |
| 02 | Xingqi Pharmaceutical (300573.SZ) | A | A | A | A | B | A |
| 03 | Hengrui Pharma (600276.SH) | A | B | C | A | B | B |
| 04 | Yunnan Baiyao (000538.SZ) | B | C | B | B | C | B |
| 05 | Haisco (002653.SZ) | A | A | B | B | B | B |

## References

- [Company Overview — Profile, executives, shareholders, business breakdown](https://longbridge.com/en/quote/002940.SZ/overview.md)
- [Financial Reports — Income, balance sheet, cash flow, dividends](https://longbridge.com/en/quote/002940.SZ/norm.md)
- [Related News](https://longbridge.com/en/quote/002940.SZ/news.md)
- [Filings — Company announcements and regulatory filings](https://longbridge.com/en/quote/002940.SZ/filings.md)

---

> **Disclaimer: This article is for reference only and does not constitute any investment advice.**